UGN-102

UGN-102 · UroGen Pharma Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for UGN-102, covering 2022-07-25 to 2024-11-04. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer [Phase 3]

See pricing